Moorfields Eye Hospital, London, England.
South Australian Institute of Ophthalmology, Royal Adelaide Hospital, University of Adelaide, South Australia, Australia.
JAMA Ophthalmol. 2014 Feb;132(2):197-204. doi: 10.1001/jamaophthalmol.2013.6077.
The literature on Merkel cell carcinoma (MCC) of the eyelid remains scarce, and there has yet to be a study using the most up-to-date TNM staging system for this rare but aggressive tumor.
To analyze the TNM stage, management, and outcomes of patients with MCC of the eyelid.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective case series of 21 patients from 5 tertiary referral centers in the United Kingdom and Australia with primary MCC of the eyelid presenting at a median age of 77 years, with median follow-up of 54 months. Tumors were staged according to the American Joint Committee on Cancer, 7th edition, TNM criteria for eyelid carcinoma and MCC.
TNM stage, treatment modalities, and clinical outcome.
The eyelid carcinoma TNM stages were T2aN0M0 for 5 patients, T2bN0M0 for 7 patients, T3aN0M0 for 4 patients, T3bN0M0 for 3 patients, T2bN1M0 for 1 patient, and T3aN1M0 for 1 patient. The MCC TNM stages were T1N0M0 for 12 patients, T2N0M0 for 7 patients, T1N1M0 for 1 patient, and T2N1M0 for 1 patient. One patient had a sentinel lymph node biopsy, and 8 patients underwent head/neck imaging. Eighteen patients underwent a wide local excision, 12 with a paraffin section and 6 with a frozen section. Two patients underwent Mohs surgery, 1 of whom required an orbital exenteration. Twelve patients (57%) received adjuvant radiotherapy, and 2 patients received chemotherapy. The local recurrence rate was 10%, the regional nodal recurrence rate was 10%, and the distant metastatic recurrence rate was 19%. The lowest T category tumor metastasizing to both regional nodes and distant locations was a T2a (eyelid TNM)/T1 (Merkel TNM) tumor measuring 8 mm. Two patients with T3a (eyelid TNM)/T2 (Merkel TNM) tumors died of metastatic MCC.
The majority of patients with MCC of the eyelid present with localized eyelid disease of T category T2 (eyelid TNM)/T1 (Merkel TNM). A wide local excision with margin control remains the mainstay of treatment, whereas the use of radiotherapy is institution specific. Tumors with a low T category are associated with regional nodal and distant metastatic disease. It may therefore be reasonable to consider a sentinel lymph node biopsy or strict regional lymph node surveillance for all MCCs of the eyelid, regardless of T category or size.
关于眼脸 Merkel 细胞癌(MCC)的文献仍然很少,并且对于这种罕见但侵袭性很强的肿瘤,尚未有研究使用最新的 TNM 分期系统。
分析眼脸 MCC 患者的 TNM 分期、治疗方法和结局。
设计、地点和参与者:这是一项回顾性病例系列研究,纳入了 21 名来自英国和澳大利亚 5 家三级转诊中心的原发性眼脸 MCC 患者,中位年龄为 77 岁,中位随访时间为 54 个月。根据美国癌症联合委员会第 7 版眼睑癌和 MCC 的 TNM 标准对肿瘤进行分期。
TNM 分期、治疗方式和临床结局。
眼脸癌的 TNM 分期为 T2aN0M0(5 例)、T2bN0M0(7 例)、T3aN0M0(4 例)、T3bN0M0(3 例)、T2bN1M0(1 例)和 T3aN1M0(1 例)。MCC 的 TNM 分期为 T1N0M0(12 例)、T2N0M0(7 例)、T1N1M0(1 例)和 T2N1M0(1 例)。1 例患者进行了前哨淋巴结活检,8 例患者进行了头颈部影像学检查。18 例患者接受了广泛局部切除术,其中 12 例行石蜡切片检查,6 例行冷冻切片检查。2 例患者接受了 Mohs 手术,其中 1 例需要眶内容剜除术。12 例患者(57%)接受了辅助放疗,2 例患者接受了化疗。局部复发率为 10%,区域淋巴结复发率为 10%,远处转移复发率为 19%。转移至区域淋巴结和远处部位的最低 T 分期肿瘤为 T2a(眼脸 TNM)/T1(Merkel TNM),大小为 8mm。2 例 T3a(眼脸 TNM)/T2(Merkel TNM)肿瘤患者死于转移性 MCC。
大多数眼脸 MCC 患者表现为局限性 T 分期 T2(眼脸 TNM)/T1(Merkel TNM)的眼脸疾病。广泛局部切除术联合切缘控制仍然是主要的治疗方法,而放疗的应用则因机构而异。T 分期较低的肿瘤与区域淋巴结和远处转移疾病相关。因此,对于所有眼脸 MCC,无论 T 分期或大小如何,都可以考虑进行前哨淋巴结活检或严格的区域淋巴结监测,这可能是合理的。